Leukemia Research

Papers
(The H4-Index of Leukemia Research is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Long-term engraftment stability of umbilical cord blood cells preserved in −135 °C mechanical freezers42
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)29
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation22
Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia21
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia21
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT20
ALK INHIBITOR PLUS VINBLASTINE FOR REFRACTORY/RELAPSED PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA: A PROSPECTIVE, ONE-ARM, OPEN-LABEL REAL-WORLD STUDY20
ANAPLASTIC LYMPHOMA KINASE INHIBITION ACTIVATES AUTOPHAGY IN ALK+ ANAPLASTIC LARGE CELL LYMPHOMA19
CLINICAL FEATURES AND TREATMENT OUTCOME OF CHILDREN WITH LYMPHOBLASTIC LYMPHOMA IN TAIWAN19
We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death17
A CASE OF B-CELL LYMPHOBLASTIC LYMPHOMA WITH PRIMARY BONE INVOLVEMENT: A MIMICKER OF RHEUMATOLOGICAL AND INFECTIOUS DISEASE17
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study16
Editorial Board15
Editorial Board14
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study14
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events14
0.098925113677979